by Barry101 | Dec 9, 2021 | Press Release, Uncategorized
OCALA, Fla., Dec. 09, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza (ESWI) virtual conference in Salzburg, Austria, on...
by Barry101 | Dec 6, 2021 | Press Release, Uncategorized
OCALA, Fla., Dec. 06, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas Equels, Chief Executive Officer of AIM, will be participating in two upcoming investor conferences. BioFlorida ConferenceMr. Equels will be participating in the...
by Barry101 | Nov 16, 2021 | Press Release, Uncategorized
OCALA, Fla., Nov. 16, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the third quarter ended September 30, 2021 and provides a business update. Third Quarter 2021 Financial Highlights: As of September 30, 2021, AIM had cash, cash...
by Barry101 | Oct 19, 2021 | Press Release, Uncategorized
OCALA, Fla., Oct. 19, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the U.S. Food and Drug Administration (FDA) for a...
by Barry101 | Oct 6, 2021 | Press Release, Uncategorized
OCALA, Fla., Oct. 06, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today released detailed safety data from a Phase 1 clinical study which supports the company’s belief that its drug Ampligen has significant potential as an intranasal therapeutic for...
